Related Experiment Videos
Aflibercept in wet AMD: specific role and optimal use
F Semeraro1, F Morescalchi, S Duse
1Department of Medical and Surgical Specialties, Radiological Specialties and Public Health, Ophthalmology Clinic, University of Brescia, Piazzale Spedali Civili 1, Brescia, Italy. semeraro@med.unibs.it
Drug Design, Development and Therapy
|August 31, 2013
Summary
Aflibercept (VEGF Trap-eye) is a novel anti-VEGF agent demonstrating non-inferiority to ranibizumab for wet age-related macular degeneration. This new treatment offers potential for less frequent injections, reducing patient burden.
Area of Science:
- Ophthalmology
- Vascular Biology
- Pharmacology
Background:
- Vascular endothelial growth factor (VEGF) drives angiogenesis and vascular permeability, crucial in wet age-related macular degeneration (AMD).
- Anti-VEGF agents are the primary strategy for managing choroidal neovascularization and visual acuity loss in wet AMD.
- Aflibercept (VEGF Trap-eye) is a newer anti-VEGF agent with high binding affinity and prolonged action.
Purpose of the Study:
- To review the efficacy and pharmacological properties of VEGF Trap-eye.
- To compare the advantages of VEGF Trap-eye against older anti-VEGF drugs.
Main Methods:
- Literature search of PubMed (1989-2013) using keywords: VEGF, age-related macular degeneration, VEGF-Trap eye, aflibercept.
- Inclusion of studies published in English.
Main Results:
- Two Phase III trials (VIEW 1 and 2) showed VEGF Trap-eye is non-inferior to ranibizumab in treating wet AMD.
- Clinical equivalence was maintained with 8-week dosing intervals for VEGF Trap-eye.
Conclusions:
- VEGF Trap-eye offers comparable efficacy to ranibizumab.
- The potential for extended dosing intervals with VEGF Trap-eye may reduce treatment burden and monitoring frequency.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
01:25Glaucoma: Overview
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...